Arsanis, a clinical-stage biopharmaceutical company focused on the development of targeted monoclonal antibodies (mAbs) for pre-emptive and post-infection treatment of serious infectious diseases, has promoted Rene Russo to President and Chief Executive.
Since joining the Waltham, MA, US-based firm as Chief Development Officer in August 2015, Russo spearheaded the strategy for clinical studies for Arsanis’ lead programme, ASN100, aimed at the prevention and treatment of serious Staphylococcus aureus infections.
Prior to Arsanis, Russo was VP, Global Medical Affairs at Cubist Pharmaceuticals for more than ten years in increasingly senior roles within research and development.
In addition to Russo’s new role, David Mantus has been appointed as Chief Development Officer. In this role he will drive strategy and planning for the continued clinical development of ASN100, along with other earlier-stage pipeline candidates. Mantus joined Arsanis in 2015, bringing more than 20 years of experience in clinical development, regulatory affairs and quality assurance, including as VP, Regulatory Affairs at Cubist Pharmaceuticals.
Arsanis has also recently recruited Ed Campanaro as SVP, Clinical Operations to oversee Arsanis' global clinical trials. Prior to joining Arsanis, Campanaro was VP, Clinical Operations and Data Management for Bluebird Bio. He was also VP, Clinical Development Operations at Cubist Pharmaceuticals, where he oversaw complex, global clinical operations programmes for a portfolio of therapies for serious infectious diseases.
Arsanis plans to advance ASN100 to Phase II clinical testing this year.
